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2352-3964/© 2015 The Authors. Published by Elsevier B.VBy controlling human immunodeﬁciency virus (HIV) replication and the highest concentrations observed in those with HIV-associated de-
allowing recovery of immune system function, combination antiretrovi-
ral therapy (cART) has revolutionised the outlook for people-living-
with-HIV (PLWH) to that of a chronic butmanageablemedical condition.
Despite this success, other medical problems, such as hypertension and
cardiovascular disease, are reported to occur more frequently and at a
younger age in PLWH compared to matched control populations
(Schouten et al., 2014). Another medical problemwith a high prevalence
and high morbidity is cognitive impairment (Robertson et al., 2007).
For many co-morbidities, surrogate markers aid diagnosis and assist
in the clinical staging of a disease state. For cognitive impairment how-
ever, disease markers to date have either been unreliable or impractical
to measure. For instance, clinical assessments such as formal neuropsy-
chological testing are time consuming to perform and prone to many
confounding issues such as illicit drug and alcohol use, the presence of
depression and anxiety, and day to day variability in a patient's
performance. Novel cerebral imaging techniques show promise in the
diagnosis and assessment of HIV-associated cognitive impairment
(Descamps et al., 2008). However, many of these novel imaging tech-
niques are not widely available and may only be accessible as part of a
research study, rather than in general clinical care. And lastly, although
cerebrospinal ﬂuid (CSF) markers, such as neuroﬁlament light protein
(NFL) concentration, show promise, collection of CSF is problematic.
Lumbar puncture, whilst generally safe, is an invasive and resource
expensive procedure which does not lend itself particularly well to
repeated measure (Peterson et al., 2014).
In this issue of EBioMedicine, Gisslen et al. (2015) report on the
measurement of plasma NFL concentrations, using a new ultrasensitive
single molecule assay, and its correlations with CSF NFL concentrations
in several cohorts of PLWH. Groups assessed included individuals with
primaryHIV-infection, neuroasymptomatic PLWHnot on cARTwith dif-
ferent ranges of CD4+ lymphocyte counts (above 350 cells/uL, 200–349
cells/uL, 50–199 cells/uL and below 50 cells/uL), individuals with overt
HIV-associated dementia and subjects on cART with plasma HIV RNA
b50 copies/mL for greater than one year. Furthermore an HIV-
uninfected control group was included in their analysis. As expected,
CSF concentration of NFL was dependent on the cohorts studied withom.2015.11.036.
tant Physician, Imperial College
).
. This is an open access article undermentia and higher concentrations in PLWH with untreated HIV-
disease and low CD4+ lymphocyte counts. Of importance, in all groups
studied, a strong correlation between plasma NFL and CSF NFL was
reported.
The values of NFL plasma concentrations were 1–2 log10 lower than
in the CSF. However, by developing and utilising this new ultrasensitive
plasma NFL assay, concentrations as low as a mean of 9.3 nmol/L were
measured in the HIV-uninfected control group and every subject had a
detectable and quantiﬁable concentration. This impressive dynamic
range highlights the potential sensitivity of this biomarker to detect
subtle axonal injury in a variety of patient groups.
The ability to utilise a sensitive plasma biomarker which closely cor-
relates with active CNS axonal injury has several potential implications
for future research. Within longitudinal cohorts, clinical observations
and non-invasive neuroimaging observations could now be correlated
with readily obtainable plasma biomarkers. Within interventional
studies, a novel plasma biomarker which correlates with the effects of
a drug or other interventions on cerebral function, could dramatically
simplify the practical issues which are currently associated with the
development of such therapeutics. Furthermore, this assay has the
potential in clinical practice, as well as research studies, to discriminate
between those with ongoing CNS injury in whom intervention may
be more successful and those with quiescent disease in whom it may
not.
In summary, these initial results described are highly promisingwith
further work needed to assess the utility of this marker in other cohorts
of PLWH, such as those with minor cognitive complaints, and other
neurodegenerative diseases.Disclosure
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